0
Research
Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis
Jennifer Elston Lafata, PhD; Mirela Cerghet, MD; Elizabeth Dobie, MPH; Lonni Schultz, PhD; Kaan Tunceli, PhD; Jacqueline Reuther, BSRN
J Am Pharm Assoc (2003) 2008;48:752-757. doi:10.1331/JAPhA.2008.07116

Abstract

Objectives  To measure disease-modifying agent adherence and persistence among patients with multiple sclerosis (MS).

Design  Retrospective cohort study.

Setting  Multispecialty, salaried group practice in southeast Michigan, between June 1, 2004, and June 30, 2006.

Patients  224 insured adult patients with relapsing remitting MS with an outpatient visit.

Main outcome measures  Medical record–documented receipt of medication recommendation and prescription. Pharmacy claims data–derived measures of dispensing and among patients with two or more dispensings, medication possession ratios (MPRs), and proportion of gap days were estimated. Among those initiating agent use, persistence was estimated.

Results  Mean cohort age was 47.6 years, while 77% of participants were women and 39% were black. Of patients, 81.8% had a recommendation for a disease-modifying agent, 75.0% had a prescription, and 66.5% had two or more dispensings. Among those with two or more dispensings, mean MPR between the first and last dispensing date was 83.8% (95% CI 80.8–86.8), while mean MPR for the entire 24-month period was 68.0% (64.4–71.7). MPR for the 24-month period decreased with increasing drug copayments and was lower among black patients, while MPR between the first and last dispensing date increased with increasing age. Among those initiating therapy, 43% were nonpersistent with medications within 14 months.

Conclusion  Medication adherence and persistence among patients with relapsing remitting MS is far from monolithic. Measuring medication adherence and persistence among defined populations is useful for understanding the relationship between medication use and outcomes in practice and for targeting patients and programs to improve medication adherence.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group.  N Engl J Med. 2000;343:898–904.[PubMed][CrossRef]
 
Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).  Lancet. 2002;359:1453–60.[PubMed]
 
Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management.  Neurologist. 2002;8:227–36.[PubMed]
 
Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis.  Neurol Sci. 2003;24:361–4.[PubMed]
 
Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.  CNS Drugs. 2002;16:825–50.[PubMed]
 
Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.  J Neurosci Nurs. 2001;33:231–9.[PubMed]
 
Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis.  J Neurosci Nurs. 2003;35:163–70.[PubMed]
 
Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment.  Mult Scler. 1996;2:222–6.[PubMed]
 
Mohr DC, Goodkin DE, Masuoka L, et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis.  Mult Scler. 1999;5:192–7.[PubMed]
 
Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject.  Ann Behav Med. 2001;23:125–32.[PubMed]
 
Berger BA, Hudmon KS, Liang H. Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change.  J Am Pharm Assoc. 2004;44:445–54.
 
Gillick MR.  Molecular medicine, the Medicare drug benefit, and the need for cost control.  J Am Geri Soc. 2006;54:1442–6.
 
Vine MF, Degnan D, Hanchette C. Geographic information systems: their use inenvironmental epidemiologic research.  Environ Health Perspect. 1997;105:598–605.[PubMed]
 
Deyo RA, Cherkin DC, Ciol MA.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.  J Clin Epidemiol. 1992;45:613–9.[PubMed]
 
DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW.  Patient adherence and medical treatment outcomes: a meta-analysis.  Med Care. 2002;40:794–811.[PubMed]
 
Dulmen  van S, Sluijs E, Dijk  van L, et al. Patient adherence to medical treatment: a review of reviews.  BMC Health Serv Res. 2007;7:55.[PubMed]
 
 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.  Neurology. 1993;43:655–61.[PubMed]
 
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG).  Ann Neurol. 1996;39:285–94.[PubMed]
 
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group.  Neurology. 1995;45:1268–76.[PubMed]
 
Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes.  Diabetes Care. 2004;27:2800–5.[PubMed]
 
Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma.  J Allergy Clin Immunol. 2004;114:1288–93.[PubMed]
 
McDonald HP, Garg AX, Haynes RB.  Interventions to enhance patient adherence to medication prescriptions: scientific review.  JAMA. 2002;288:2868–79.[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints